Understanding NINLARO®

Ninlaro® (ixazomib) is the first FDA-approved proteasome inhibitor used in the treatment of myeloma that is taken by mouth in capsule form rather than being administered intravenously. Ninlaro is approved in combination with the immunomodulatory agent Revlimid® (lenalidomide) and the steroid dexamethasone, a three-drug combination known as “IRd,” for the treatment of patients who have received at least one prior therapy.

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.